<DOC>
	<DOCNO>NCT02772614</DOCNO>
	<brief_summary>The purpose study : To determine rate route excretion BIA 3-202 mass balance urine faeces To determine kinetics total radioactivity blood To determine kinetics total radioactivity plasma To determine kinetics BIA 3-202 metabolite plasma</brief_summary>
	<brief_title>Absorption , Distribution , Metabolism Excretion 14C-Labelled BIA 3-202 Metabolites</brief_title>
	<detailed_description>Monocentre , open , non-placebo-controlled , single-group , single-dose study . Safety measurement ( 12-lead ECG , vital sign , blood chemistry haematology ) conduct study , adverse event monitor throughout study . Each subject receive single oral dose 2.5 MBq [ 14C ] -labelled BIA 3-202 ( 200 mg ) . This intend radiolabelled dose without loss ; actual administer dose 2.29 MBq [ 14C ] -labelled BIA 3-202 ( 200 mg ) . Subjects hospitalize day administration 264 hour thereafter . Whole blood sample ( 2 mL ) total radioactivity analysis , plasma sample ( 1.5 mL ) total radioactivity analysis , plasma sample ( 7 mL ) analysis BIA 3-202 metabolite collect follow time : pre-dose 0.25 , 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , 12 , 24 , 36 , 48 , 72 , 120 , 168 , 216 , 264 hour post-dose . Urine sample drug administration ( pre-dose ) , collect 0-4 , 4-8 , 8-24 , 24-48 , 48-72 , 72-120 , 120-168 , 168-216 , 216-264 hour post-dose . Aliquots sample take liquid scintillation count investigator . Aliquots separate determination parent drug metabolite pattern . A baseline faeces sample obtain screening baseline period . Following dose , faeces sample collect separate container 264 hour post-dose period . Vomitus ( produce ) collect .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>1 . Healthy male subject , 4055 year age . Take Caucasians . 2 . Clinically acceptable sit blood pressure pulse rate , i.e . : BP : 110160 mmHg systolic , 6595 mmHg diastolic pulse rate : 50100 bpm . Blood pressure pulse measure 3 minute rest sit position . 3 . Subject body weight must 50 95 kg within 10 % / +20 % normal height frame size ( accord Metropolitan Life Insurance Table , see Appendix 1 &amp; 2 Study Protocol ) . Frame size determine use elbow breadth measurement . 4 . Normal 12lead ECG . 5 . Ability communicate well investigator comply requirement entire study . 6 . The subject give write informed consent participate study . 1 . History serious adverse reaction hypersensitivity drug . 2 . Presence history allergy require acute chronic treatment ( except seasonal allergic rhinitis ) . 3 . History alcohol drug abuse last 5 year . 4 . Abnormal physical finding clinical significance screen examination baseline would interfere objective study . 5 . Need prescription medication within 14 day prior administration drug and/or nonprescription medication within 7 day prior administration drug . 6 . Participation clinical trial previous month investigational drug commercially available drug test . 7 . Loss 500 mL blood 3 month period study , e.g. , donor . 8 . Existence surgical medical condition might interfere absorption , distribution , metabolism excretion drug , i.e. , impair renal hepatic function , diabetes mellitus , cardiovascular abnormality , chronic symptom pronounce constipation diarrhoea condition associate total partial obstruction urinary tract . 9 . Symptoms significant somatic mental illness 4 week period precede drug administration . 10 . History hepatitis B / C / positive serology result indicate presence hepatitis B / C. 11 . Positive result HIV serology . 12 . Clinically significant abnormal laboratory value ( determine Principal Investigator ) screen evaluation , however , liver parameter ( SGPT , SGOT ) CK value must within normal range . 13 . Positive result drug screening . 14 . Known hypersensitivity BIA 3202 . 15 . Heavy smoker , i.e. , 10 cigarette per day . 16 . Exposure artificial ionizing radiation last 12 month ( e.g. , xray investigation ) . 17 . Subject 4 flight ( 2 hour flight time ) within last year prior administration drug .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Nebicapone , Parkinson 's disease</keyword>
</DOC>